OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

MLA

A. Sacher, et al. “OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation.” Journal of Thoracic Oncology, vol. 17, Sept. 2022, pp. S8–9. EBSCOhost, https://doi.org/10.1016/j.jtho.2022.07.023.

APA

A. Sacher, M.R. Patel, W.H. Miller, J. Desai, E. Garralda, S. Bowyer, T.W. Kim, M. De Miguel, A. Falcon, M.G. Krebs, J. Lee, M. Cheng, S.-W. Han, E. Shacham-Shmueli, M. Forster, G. Jerusalem, E. Massarelli, L. Paz-Ares Rodriguez, H. Prenen, … P. LoRusso. (2022). OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation. Journal of Thoracic Oncology, 17, S8–S9. https://doi.org/10.1016/j.jtho.2022.07.023

Chicago

A. Sacher, M.R. Patel, W.H. Miller, J. Desai, E. Garralda, S. Bowyer, T.W. Kim, et al. 2022. “OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation.” Journal of Thoracic Oncology 17 (September): S8–9. doi:10.1016/j.jtho.2022.07.023.